Abstract
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).
Original language | English (US) |
---|---|
Pages (from-to) | 844-851 |
Number of pages | 8 |
Journal | British journal of haematology |
Volume | 191 |
Issue number | 5 |
DOIs | |
State | Published - Dec 2020 |
Keywords
- ABL-class fusion
- paediatric acute lymphoblastic leukaemia
- prognostic factors
- targeted therapy
- tyrosine kinase inhibitor
ASJC Scopus subject areas
- Hematology